VANCOUVER, British Columbia, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), announces it is in the process of obtaining NSF Certification for its facility to ensure the Company is able to market its products to consumers with NSF accreditation. Chemesis has engaged with a senior consultant that has a background in nutraceuticals as well as obtaining facility and product certifications.

The mission of NSF International is to protect public health, a mission we share with regulatory agencies and personnel whose job is to do the same. NSF International is an American testing, inspection and certification organization renowned in the pharma, nutraceutical and food industry for their compliancy standards. Products made from an NSF certified facility are accepted as the highest quality by consumers around the world.

This certification will allow the Company to manufacture its tobacco-free chew products under global GMP standards. The certification gives consumers added peace of mind that the products they purchase have been produced in an NSF certified facility. The Company will work towards gaining NSF certification before calendar Q1 2020.

In addition, the Company has begun the process of obtaining Natural Product Number (“NPN”) approvals from Health Canada for our tobacco-free hemp-derived chew products to market in Canada. Once approvals are obtained, the Company may distribute hemp-based chew products throughout the country as a natural health product. This approval method allows the Company to distribute throughout Canadian natural food, large retail chains, pharmacies and convenience stores.

"The NSF certification is widely accepted as a certification that brings very high standard manufacturing procedures," said Chemesis CEO, Edgar Montero. "Through the NSF certification, we are able to provide higher quality and peace of mind to our consumers. The Company is working closely with industry experts to ensure the facility is certified to meet the highest standards. In conjunction with the development of our product catalogue, Chemesis will begin the process of getting its NPN approval for distribution throughout Canada.”

On Behalf of The Board of Directors
Edgar Montero
CEO and Director

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico and Colombia.

The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands that cater to a wide community of cannabis consumers, with focus on quality and consistency. 

Chemesis has facilities in both Puerto Rico and California and is in the process of constructing a GMP certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space. The Company is positioned to win additional licenses in highly competitive merit-based US states and will expand its footprint to ensure it maintains a first mover advantage.

Investor Relations:
ir@chemesis.com
1 (604) 398-3378

Social Media:

Chemesis.facebook
Chemesis.twitter
Chemesis.instagram
DesertZen.instagram
GreenSpiritRX

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future of the Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in Colombia, including with respect to its expected ability to produce and launch commercial sales of a tobacco-free, smokeless chew by Q4 2019 (or at all), the potential size of the market for such products, the potential health benefits of such products, and its ability to acquire any new cannabis production or distribution licenses, and to expand its retail dispensary network. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release, including that it may not be successful in producing or launching commercial sales of a tobacco-free, smokeless chew by Q4 2019 (or at all), that significant market demand for such products may not materialize, that such products may not carry the expected (or any) potential health benefits over tobacco-containing chews already on the market, that it may be unable to acquire any new cannabis production or distribution licenses or to expand its retail dispensary network,  and generally that the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release